Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

SHPH vs ATNM vs CELC vs ISRG

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SHPH
Shuttle Pharmaceuticals Holdings, Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$4M
5Y Perf.-100.0%
ATNM
Actinium Pharmaceuticals, Inc.

Biotechnology

HealthcareAMEX • US
Market Cap$38M
5Y Perf.-82.6%
CELC
Celcuity Inc.

Biotechnology

HealthcareNASDAQ • US
Market Cap$5.66B
5Y Perf.+1298.0%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+120.4%

SHPH vs ATNM vs CELC vs ISRG — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SHPH logoSHPH
ATNM logoATNM
CELC logoCELC
ISRG logoISRG
IndustryDrug Manufacturers - Specialty & GenericBiotechnologyBiotechnologyMedical - Instruments & Supplies
Market Cap$4M$38M$5.66B$161.07B
Revenue (TTM)$0.00$90K$0.00$10.58B
Net Income (TTM)$-11M$-35M$-163M$2.98B
Gross Margin-8.1%66.3%
Operating Margin-414.9%30.5%
Forward P/E43.8x
Total Debt$1M$2M$98M$303M
Cash & Equiv.$2M$73M$23M$3.37B

SHPH vs ATNM vs CELC vs ISRGLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SHPH
ATNM
CELC
ISRG
StockAug 22May 26Return
Shuttle Pharmaceuti… (SHPH)1000.0-100.0%
Actinium Pharmaceut… (ATNM)10017.4-82.6%
Celcuity Inc. (CELC)1001398.0+1298.0%
Intuitive Surgical,… (ISRG)100220.4+120.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: SHPH vs ATNM vs CELC vs ISRG

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: ISRG leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Celcuity Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
SHPH
Shuttle Pharmaceuticals Holdings, Inc.
The Specific-Use Pick

SHPH plays a supporting role in this comparison — it may shine differently against other peers.

Best for: healthcare exposure
ATNM
Actinium Pharmaceuticals, Inc.
The Secondary Option

ATNM lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
CELC
Celcuity Inc.
The Long-Run Compounder

CELC is the #2 pick in this set and the best alternative if long-term compounding is your priority.

  • 8.1% 10Y total return vs ISRG's 5.5%
  • +11.8% vs SHPH's -89.1%
Best for: long-term compounding
ISRG
Intuitive Surgical, Inc.
The Income Pick

ISRG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • beta 1.02
  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
  • Beta 1.02, current ratio 4.87x
Best for: income & stability and growth exposure
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs ATNM's -100.0%
Quality / MarginsISRG logoISRG28.2% margin vs ATNM's -384.4%
Stability / SafetyISRG logoISRGBeta 1.02 vs CELC's 1.71, lower leverage
DividendsTieNone of these 4 stocks pay a meaningful dividend
Momentum (1Y)CELC logoCELC+11.8% vs SHPH's -89.1%
Efficiency (ROA)ISRG logoISRG14.8% ROA vs SHPH's -253.9%, ROIC 15.0% vs -456.4%

SHPH vs ATNM vs CELC vs ISRG — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SHPHShuttle Pharmaceuticals Holdings, Inc.

Segment breakdown not available.

ATNMActinium Pharmaceuticals, Inc.
FY 2023
Other Revenue Member
100.0%$81,000
CELCCelcuity Inc.

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B

SHPH vs ATNM vs CELC vs ISRG — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLISRGLAGGINGATNM

Income & Cash Flow (Last 12 Months)

ISRG leads this category, winning 4 of 5 comparable metrics.

ISRG and CELC operate at a comparable scale, with $10.6B and $0 in trailing revenue. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to ATNM's -384.4%.

MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
RevenueTrailing 12 months$0$90,000$0$10.6B
EBITDAEarnings before interest/tax-$11M-$37M-$159M$3.8B
Net IncomeAfter-tax profit-$11M-$35M-$163M$3.0B
Free Cash FlowCash after capex-$11M-$25M-$145M$2.8B
Gross MarginGross profit ÷ Revenue-8.1%+66.3%
Operating MarginEBIT ÷ Revenue-414.9%+30.5%
Net MarginNet income ÷ Revenue-384.4%+28.2%
FCF MarginFCF ÷ Revenue-278.2%+26.8%
Rev. Growth (YoY)Latest quarter vs prior year+23.0%
EPS Growth (YoY)Latest quarter vs prior year-183.8%+56.8%-31.4%+18.8%
ISRG leads this category, winning 4 of 5 comparable metrics.

Valuation Metrics

Evenly matched — ATNM and CELC each lead in 1 of 2 comparable metrics.
MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
Market CapShares × price$4M$38M$5.7B$161.1B
Enterprise ValueMkt cap + debt − cash$3M-$33M$5.7B$158.0B
Trailing P/EPrice ÷ TTM EPS-0.00x-0.96x-46.19x57.62x
Forward P/EPrice ÷ next-FY EPS est.43.84x
PEG RatioP/E ÷ EPS growth rate2.65x
EV / EBITDAEnterprise value multiple43.62x
Price / SalesMarket cap ÷ Revenue16.00x
Price / BookPrice ÷ Book value/share10.28x1.12x44.60x9.17x
Price / FCFMarket cap ÷ FCF64.67x
Evenly matched — ATNM and CELC each lead in 1 of 2 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 7 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-5 for SHPH. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHPH's 1.65x. On the Piotroski fundamental quality scale (0–9), ISRG scores 6/9 vs CELC's 1/9, reflecting solid financial health.

MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
ROE (TTM)Return on equity-4.8%-151.7%-179.0%+16.9%
ROA (TTM)Return on assets-2.5%-52.3%-58.0%+14.8%
ROICReturn on invested capital-4.6%-50.3%+15.0%
ROCEReturn on capital employed-2.6%-59.5%-58.0%+16.5%
Piotroski ScoreFundamental quality 0–92316
Debt / EquityFinancial leverage1.65x0.05x0.85x0.02x
Net DebtTotal debt minus cash-$746,672-$71M$75M-$3.1B
Cash & Equiv.Liquid assets$2M$73M$23M$3.4B
Total DebtShort + long-term debt$1M$2M$98M$303M
Interest CoverageEBIT ÷ Interest expense-50.60x-5.02x
ISRG leads this category, winning 7 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

CELC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in CELC five years ago would be worth $48,161 today (with dividends reinvested), compared to $1 for SHPH. Over the past 12 months, CELC leads with a +1184.0% total return vs SHPH's -89.1%. The 3-year compound annual growth rate (CAGR) favors CELC at 140.6% vs SHPH's -86.0% — a key indicator of consistent wealth creation.

MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
YTD ReturnYear-to-date-61.0%-10.9%+30.0%-19.3%
1-Year ReturnPast 12 months-89.1%-12.9%+1184.0%-15.4%
3-Year ReturnCumulative with dividends-99.7%-85.9%+1292.0%+49.6%
5-Year ReturnCumulative with dividends-100.0%-83.3%+381.6%+58.7%
10-Year ReturnCumulative with dividends-100.0%-97.7%+814.7%+554.2%
CAGR (3Y)Annualised 3-year return-86.0%-47.9%+140.6%+14.4%
CELC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CELC and ISRG each lead in 1 of 2 comparable metrics.

ISRG is the less volatile stock with a 1.02 beta — it tends to amplify market swings less than CELC's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CELC currently trades 86.6% from its 52-week high vs SHPH's 6.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
Beta (5Y)Sensitivity to S&P 5001.24x1.40x1.71x1.02x
52-Week HighHighest price in past year$11.25$1.95$151.02$603.88
52-Week LowLowest price in past year$0.50$0.95$9.51$427.84
% of 52W HighCurrent price vs 52-week peak+6.3%+62.6%+86.6%+75.1%
RSI (14)Momentum oscillator 0–10043.352.863.442.4
Avg Volume (50D)Average daily shares traded840K184K800K1.8M
Evenly matched — CELC and ISRG each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CELC as "Buy", ISRG as "Buy". Consensus price targets imply 37.3% upside for ISRG (target: $623) vs -4.6% for CELC (target: $125).

MetricSHPH logoSHPHShuttle Pharmaceu…ATNM logoATNMActinium Pharmace…CELC logoCELCCelcuity Inc.ISRG logoISRGIntuitive Surgica…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$124.75$622.60
# AnalystsCovering analysts955
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises0
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%0.0%+1.4%
Insufficient data to determine a leader in this category.
Key Takeaway

ISRG leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CELC leads in 1 (Total Returns). 2 tied.

Best OverallIntuitive Surgical, Inc. (ISRG)Leads 2 of 6 categories
Loading custom metrics...

SHPH vs ATNM vs CELC vs ISRG: Key Questions Answered

9 questions · data-driven answers · updated daily

01

Is SHPH or ATNM or CELC or ISRG a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). Intuitive Surgical, Inc. (ISRG) offers the better valuation at 57. 6x trailing P/E (43. 8x forward), making it the more compelling value choice. Analysts rate Celcuity Inc. (CELC) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which is the better long-term investment — SHPH or ATNM or CELC or ISRG?

Over the past 5 years, Celcuity Inc.

(CELC) delivered a total return of +381. 6%, compared to -100. 0% for Shuttle Pharmaceuticals Holdings, Inc. (SHPH). Over 10 years, the gap is even starker: CELC returned +814. 7% versus SHPH's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

03

Which is safer — SHPH or ATNM or CELC or ISRG?

By beta (market sensitivity over 5 years), Intuitive Surgical, Inc.

(ISRG) is the lower-risk stock at 1. 02β versus Celcuity Inc. 's 1. 71β — meaning CELC is approximately 68% more volatile than ISRG relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 165% for Shuttle Pharmaceuticals Holdings, Inc. — giving it more financial flexibility in a downturn.

04

Which is growing faster — SHPH or ATNM or CELC or ISRG?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -100. 0% for Actinium Pharmaceuticals, Inc. (ATNM). On earnings-per-share growth, the picture is similar: Actinium Pharmaceuticals, Inc. grew EPS 30. 6% year-over-year, compared to -2159. 3% for Shuttle Pharmaceuticals Holdings, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

05

Which has better profit margins — SHPH or ATNM or CELC or ISRG?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -384. 4% for Actinium Pharmaceuticals, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -414. 9% for ATNM. At the gross margin level — before operating expenses — ISRG leads at 66. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

06

Is SHPH or ATNM or CELC or ISRG more undervalued right now?

Analyst consensus price targets imply the most upside for ISRG: 37.

3% to $622. 60.

07

Which pays a better dividend — SHPH or ATNM or CELC or ISRG?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

08

Is SHPH or ATNM or CELC or ISRG better for a retirement portfolio?

For long-horizon retirement investors, Intuitive Surgical, Inc.

(ISRG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 02), +554. 2% 10Y return). Both have compounded well over 10 years (ISRG: +554. 2%, ATNM: -97. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

09

What are the main differences between SHPH and ATNM and CELC and ISRG?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SHPH is a small-cap quality compounder stock; ATNM is a small-cap quality compounder stock; CELC is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

SHPH

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ATNM

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

CELC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.